aceAI-Assisted Analysis of Clinical Trials to Identify Failed Drugs for Revival via Drug Delivery Technologies
Numerous drug candidates showed great promise in experimental and preclinical investigations but failed in clinical trials. One cause to this problem may be nonspecific drug biodistribution, leading to adverse effects in healthy organs. Drug delivery technologies are developed to overcome this exact problem by navigating drugs more selectively to the disease sites. Therefore, they hold the promise to revive at least some failed drugs. However, it is challenging to identify such candidates revivable by drug deliv…
An OpenAI-based framework classified terminated trials with 88.66% to 91.75% validation accuracy and flagged 817 trials possibly failed due to unwanted drug biodistribution, plus ten candidate small molecules.
The study addresses only the language problem; the lack of systematic patient biodistribution data remains unsolved, and the 817 trials are only possibly failed due to unwanted biodistribution.
Evidence
- Peer-reviewedMolecular Pharmaceutics2026-11-02
How should this claim be treated?
Truvace Impact Record TRV-2026-2336, v1: “AI-Assisted Analysis of Clinical Trials to Identify Failed Drugs for Revival via Drug Delivery Technologies.” Truvace, 2026-11-02. /record/TRV-2026-2336 (accessed at citation time). sha256 4971dcfad108c4a8…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-2336 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.